Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking
- PMID: 3121231
- DOI: 10.1038/clpt.1988.7
Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking
Abstract
The effects of tobacco and oral contraceptive (OC) use (Ovral) on the pharmacokinetics of levonorgestrel (0.25 mg) and ethinyl estradiol (50 micrograms) were examined. Young women (n = 27) were grouped as follows: I: non-OC users/nonsmokers; II: OC users/nonsmokers; III: non-OC users/smokers; and IV: OC users/smokers. The apparent clearance of levonorgestrel in group I was 80.9 +/- 15.6 ml/hr/kg and the half-life was 19.3 hours. A significant decrease in levonorgestrel clearance was seen in the chronic OC users (groups II and IV). The apparent oral clearance of ethinyl estradiol was 1002 +/- 398 ml/hr/kg in group I and the half-life averaged 7.7 hours. Groups II and III showed decreased (not significant) clearance of ethinyl estradiol. Tobacco use had no effect on steroid pharmacokinetics in the non-OC users. Although chronic OC use did not affect ethinyl estradiol clearance, a joint effect of tobacco/OC use on enhancing clearance of ethinyl estradiol appeared to occur. A linear relationship was found between 24-hour trough serum concentrations and AUC values of both steroids that may facilitate population monitoring studies of OC exposure.
PIP: The effects of combined cigarette smoking and oral contraceptive (OC) use on the pharmacokinetics of the pill's major components were examined in 27 white female volunteers grouped as follows: Group 1, non-OC user, nonsmoker; Group 2, OC user, nonsmoker; Group 3, non-OC user, smoker; Group 4, OC user, smoker. The 11 OC users in the study had been taking the pill for over 6 months; 5 were taking Ovral (50 mcg of ethinyl estradiol, 0.5 mg of norgestrel) and the remaining 6 switched to Ovral for the 1-month cycle before the study period. The non-OC users took 1 study dose of Ovral. The clearance of levonorgestrel was significantly lower in chronic OC users (mean elimination half-life of 30 hours) than in single-dose subjects (mean elimination half-life of 23 hours). The mean elimination half-life of ethinyl estradiol was approximately 12 hours for both chronic and acute OC use, although there was a nonsignificant tendency for lower ethinyl estradiol clearances in chronic OC users. Chronic tobacco use as a single factor did not influence the pharmacokinetics of levonorgestrel; however, a joint effect from chronic OC use and tobacco use was seen for ethinyl estradiol. Tobacco use had no effect on steroid pharmacokinetics in the non-OC users. Finally, a linear relationship was found between 24-hour trough serum concentrations and area-under-curve values of both steroids that may facilitate population monitoring studies of OC exposure.
Similar articles
-
Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.Am J Obstet Gynecol. 1980 Apr 1;136(7):920-31. doi: 10.1016/0002-9378(80)91052-2. Am J Obstet Gynecol. 1980. PMID: 6767404 Clinical Trial.
-
Effects of tobacco smoking and oral contraceptive use on theophylline disposition.Br J Clin Pharmacol. 1983 Sep;16(3):271-80. doi: 10.1111/j.1365-2125.1983.tb02161.x. Br J Clin Pharmacol. 1983. PMID: 6626419 Free PMC article.
-
Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.Contraception. 1992 Nov;46(5):455-69. doi: 10.1016/0010-7824(92)90149-n. Contraception. 1992. PMID: 1458892 Clinical Trial.
-
Pharmacokinetics of gestagens: some problems.Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):323-8. doi: 10.1016/0002-9378(90)90576-s. Am J Obstet Gynecol. 1990. PMID: 2115297 Review.
-
Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.Contraception. 1988 Jul;38(1):27-35. doi: 10.1016/0010-7824(88)90093-5. Contraception. 1988. PMID: 3139358 Review.
Cited by
-
Estimating systemic exposure to levonorgestrel from an oral contraceptive.Contraception. 2017 Apr;95(4):398-404. doi: 10.1016/j.contraception.2016.12.007. Epub 2016 Dec 30. Contraception. 2017. PMID: 28041990 Free PMC article.
-
Levonorgestrel. Clinical pharmacokinetics.Clin Pharmacokinet. 1995 Mar;28(3):203-15. doi: 10.2165/00003088-199528030-00003. Clin Pharmacokinet. 1995. PMID: 7758251 Review.
-
Smoking and recurrent attacks of acute intermittent porphyria.BMJ. 1991 Mar 2;302(6775):507. doi: 10.1136/bmj.302.6775.507. BMJ. 1991. PMID: 2012848 Free PMC article. No abstract available.
-
Transdermal patches: history, development and pharmacology.Br J Pharmacol. 2015 May;172(9):2179-209. doi: 10.1111/bph.13059. Epub 2015 Mar 18. Br J Pharmacol. 2015. PMID: 25560046 Free PMC article. Review.
-
Experts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4).Front Glob Womens Health. 2024 Apr 9;5:1395863. doi: 10.3389/fgwh.2024.1395863. eCollection 2024. Front Glob Womens Health. 2024. PMID: 38655395 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources